Researchers at Michigan State University have received a five-year $2.3 million grant to learn how the omega-3 fatty acid…
Magdalena Kegel
Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Magdalena Kegel
Aurinia Pharmaceuticals has started a Phase 3 clinical trial of voclosporin, which eliminated an inflammatory kidney condition known as…
Lupus patients should be checked for heart-valve abnormalities because the disease increases the risk of the heart condition, according to a…
EpiVax has licensed its Tregitope technology — a new approach to harnessing the power of regulatory T-cells in autoimmune…
A super-sensitive assay, capable of detecting minute amounts of the immune factor interferon-alpha, will aid physicians in diagnosing systemic lupus…
Monthly intravenous Cytoxan (cyclophosphamide) treatment was linked to a lower accumulation of lupus nephritis kidney damage than other induction therapies…
Infants with neonatal lupus syndrome can have autoantibodies that fight other autoantibodies. In this case, the autoantibodies doing the targeting are…
New insights into immune cell processes in patients with systemic lupus erythematosus may advance scientists’ understanding of how the immune…
Treating newly diagnosed systemic lupus erythematosus patients with Rituxan (rituximab) is safe and effective, according to a study that followed…
The discovery of a factor that acts as a brake on the immune system’s first line of defense may lead…